Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.

abstract

• Fidaxomicin (FDX) is approved to treat Clostridium difficile-associated diarrhea and is superior to vancomycin in providing a sustained clinical response (cure without recurrence in the subsequent 25 days). The mechanism(s) behind the low recurrence rate of FDX-treated patients could be multifactorial. Here, we tested effects of FDX, its metabolite OP-1118, and vancomycin on spore germination and determined that none affected the initiation of spore germination but all inhibited outgrowth of vegetative cells from germinated spores.

authors

• Sorg, Joseph

published proceedings

• Antimicrob Agents Chemother

altmetric score

• 3.75

author list (cited authors)

• Allen, C. A., Babakhani, F., Sears, P., Nguyen, L. y., & Sorg, J. A.

citation count

• 56

complete list of authors

• Allen, Charlotte A||Babakhani, Farah||Sears, Pam||Nguyen, Ly||Sorg, Joseph A

publication date

• January 2013

publisher

• American Society for Microbiology  Publisher

published in

• Antimicrobial Agents and Chemotherapy  Journal

keywords

• Aminoglycosides
• Anti-Bacterial Agents
• Clostridioides Difficile
• Culture Media
• Fidaxomicin
• Microbial Sensitivity Tests
• Spores, Bacterial
• Taurocholic Acid
• Vancomycin

Digital Object Identifier (DOI)

• 10.1128/AAC.01611-12

start page

• 664

end page

• 667

volume

• 57

issue

• 1

URL

• http://dx.doi.org/10.1128/aac.01611-12